Skip to main content
TanyaKanker

Advanced treatment

CAR-T (chimeric antigen receptor T-cell therapy)

Cell therapy that modifies a patient's T cells to recognise a marker on cancer cells, then returns them to the patient.

Upload ReportClinical trials in this category
Diagram perjalanan CAR-T: sel T diambil, direkayasa, diperbanyak, dikembalikan, mengenali sel kanker
Terapi selulerDraft, not yet medically reviewed

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.

What is it?

The CAR-T process begins with taking the patient's T cells via apharesis, modification in the laboratory, then re-infusion after lymphodeplexy.

Because the production process takes time, patient conditions and illnesses need to be managed during the waiting period.

This therapy requires close monitoring because reactions such as cytokine release syndrome and neurological disorders may occur.

Availability is strictly limited to facilities with cellular therapy programs and associated permits.

The patient's T cells are given a special receptor (CAR) that recognizes markers on cancer cells, such as CD19 or BCMA, so that the T cells can attack those cells.
How CAR-T (chimeric antigen receptor T-cell therapy)

How it works

The patient's T cells are given a special receptor (CAR) that recognizes markers on cancer cells, such as CD19 or BCMA, so that the T cells can attack those cells.

Position in the treatment pathway: Commonly discussed in relapsed or refractory B-cell lymphoma or multiple myeloma after multiple lines of therapy, and in some other blood cell malignancies.

Ilustrasi terapi sel: sel imun diprogram di laboratorium sebelum dikembalikan ke pasien

Visual explainer

CAR-T therapy journey

From immune-cell collection and laboratory engineering to infusion and monitoring - and when CAR-T starts to be discussed for relapsed lymphoma.

View the CAR-T journey

Which cancers is it usually discussed for?

Usually considered

  • Target markers are confirmed to be present on cancer cells, for example CD19 or BCMA.
  • History of previous therapy according to applicable criteria.
  • Organ conditions and disease status that enable the production and monitoring process.

Usually not a candidate

  • Absence of target markers on cancer cells.
  • Certain medical conditions that make the risk unacceptable.
  • Facilities that do not have a cellular therapy program.

What is the process like?

  1. Preparation 1

    Confirmation of recent pathological markers.

  2. Preparation 2

    Evaluation of organs, active infection, and disease status.

  3. Preparation 3

    Planning for apharesis and lymphodeplexy if the criteria are met.

  4. Monitoring

    Close monitoring in the early period after infusion.

All preparation

  • Confirmation of recent pathological markers.
  • Evaluation of organs, active infection, and disease status.
  • Planning for apharesis and lymphodeplexy if the criteria are met.

All monitoring

  • Close monitoring in the early period after infusion.
  • Monitoring infection and blood cell recovery.
  • Evaluate response with imaging and supporting examinations.

Risks and points to watch

Side-effect notes, not a complete list

This list covers categories commonly discussed. Individual risk is always assessed by the treating team.
  • Cytokine release syndrome can appear as fever, low blood pressure, and shortness of breath.
  • Neurological disorders may occur that need to be recognized quickly.
  • The risk of infection and a prolonged decrease in blood cells in some patients.

Cost and access

Cost figures depend heavily on location, facility and payer. We do not show estimated figures on this page; what can be prepared first are the questions.

  • Axicabtagene ciloleucel

    T cell therapy with chimeric antigen receptor (CAR-T) anti-CD19

    • Available only in facilities with cellular therapy programs and related permits.
    • Requires apharesis process, laboratory production, and monitoring maintenance.
    • The financing route is usually through a special scheme, not regular drug purchases.

  • Tisagenlecleucel

    Anti-CD19 CAR-T therapy

    • Limited to facilities with cellular therapy programs.
    • It requires a time-consuming cell production process and special monitoring.
    • Financing lines need to be confirmed with the facility.

  • Brexucabtagene autoleucel

    Anti-CD19 CAR-T therapy

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Idecabtagene vicleucel

    Anti-BCMA CAR-T therapy

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.

  • Ciltacabtagene autoleucel

    Anti-BCMA CAR-T therapy

    • Availability may vary between health facilities and changes over time.
    • Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
    • Prices are not listed because they cannot be verified responsibly.
Treatment cost toolCost information centreCara meminta perkiraan biaya pengobatan: dokumen dan informasi yang diperlukan

Providers and clinical trials

Access status not yet verified

Studies are filtered from the public registry. Site readiness and international patient acceptance still need confirmation before any travel is planned.
View all studies in this categoryExplore hospitals

Questions for the doctor

  • Does this facility have a CAR-T program and related permits?
  • How long does the apharesis to infusion process usually take?
  • What is the monitoring plan after the infusion and where will the patient be treated?
  • Are there clinical trials of cellular therapy that might be appropriate?

Sources

Is CAR-T (chimeric antigen receptor T-cell therapy) relevant for my case?

Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.

Upload ReportRequest a second opinion

  1. Upload reports

    Photos or PDFs of pathology, biomarkers, imaging and treatment history.

  2. Case structured

    Documents are turned into a structured case summary.

  3. Navigator review

    A human navigator checks completeness before anything is shared.

  4. Provider review

    With your consent, the case is discussed with providers for assessment and a written quote.

Is CAR-T (chimeric antigen receptor T-cell therapy) relevant for my case?

Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.

Consult via WhatsAppUpload Medical Reports

After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.

Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.

Next steps

These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.

Next to learn

To check

What you can do

  • Upload medical reports

    Build a case summary in twelve steps

    Reason: Often the most useful next step after reading this page

  • Request a second opinion

    Review of the treatment plan

    Reason: Relevant when a treatment plan is being considered

  • Consult a navigator

    A request is recorded with this page context

    Reason: For asking the next step directly

Recently updated

Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.

Upload ReportSecond Opinion

Prepare for your next consultation

Use the free six-question tool to prepare questions for your doctor.

Start free · 6 questionsContact a navigatorSaved pages